Mesoblast Limited (NASDAQ:MESO - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Mesoblast in a report released on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer anticipates that the company will post earnings of ($0.39) per share for the year. Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Mesoblast's current full-year earnings is ($0.70) per share.
Mesoblast Stock Performance
Shares of MESO stock traded down $0.38 during midday trading on Tuesday, reaching $11.78. 123,530 shares of the stock were exchanged, compared to its average volume of 272,563. Mesoblast has a 1 year low of $5.78 and a 1 year high of $22.00. The company's 50 day moving average is $11.22 and its two-hundred day moving average is $14.02. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21.
Institutional Investors Weigh In On Mesoblast
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Barclays PLC bought a new stake in shares of Mesoblast during the 4th quarter valued at $38,000. Lindbrook Capital LLC lifted its position in Mesoblast by 70.9% during the 4th quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock valued at $43,000 after acquiring an additional 901 shares during the period. JPMorgan Chase & Co. bought a new stake in Mesoblast during the fourth quarter worth about $50,000. BNP Paribas Financial Markets grew its holdings in Mesoblast by 86,566.7% in the fourth quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock worth $51,000 after purchasing an additional 2,597 shares during the period. Finally, Advisors Preferred LLC increased its stake in shares of Mesoblast by 224.9% during the first quarter. Advisors Preferred LLC now owns 4,578 shares of the company's stock valued at $54,000 after purchasing an additional 3,169 shares in the last quarter. 1.43% of the stock is owned by hedge funds and other institutional investors.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
See Also
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
